DelveInsight’s Oral Mucositis Market Insights Report offers a detailed analysis of the disease, its causes, symptoms, diagnostics modalities, and treatment options.
The Oral Mucositis market report also offers comprehensive insights into Oral Mucositis market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies actively pushing Oral Mucositis market size growth forward.
Some of the key highlights from the Oral Mucositis Market Insights Report:
- In the year 2020, the total Oral Mucositis incident cases were 1,480,453 cases in the 7MM. These cases are expected to grow in the study period 2018–2030.
- As per the DelveInsight estimates, in the United States, the total Grade-specific Oral Mucositis incident cases were highest for Grade III, with 209,660 patients in the year 2020. These cases are expected to grow in the study period 2018–2030.
- In Germany, the total treated cases of Oral Mucositis were 116,300 in the year 2020. These cases are expected to grow in the study period 2018–2030.
- Major players such as Galera Therapeutics, Soligenix, Monopar Therapeutics, NeoMedLight, BrainCool, MuReva (Lumitex), Oncozenge, and others are involved in developing therapies for the treatment and management of Oral Mucositis. These therapies are currently under different stages of development.
- Key pipeline therapies in the Oral Mucositis market include Avasopasem (GC4419), SGX942, Validive (Clonidine Lauriad), CareMin650, Cooral/CoolPrevent, MuReva Phototherapy System, BupiZenge, among others.
Learn more by requesting for sample @ Oral Mucositis Market Landscape
Oral Mucositis: Overview
Oral mucositis refers to erythematous and ulcerative lesions of the oral mucosa observed in patients with cancer being treated with chemotherapy and with radiation therapy to fields involving the oral cavity. This can lead to several problems, including pain, nutritional problems resulting from the inability to eat, and an increased risk of infection due to open sores in the mucosa. It has a significant effect on the patient’s quality of life and can be dose-limiting. This condition generally begins 5-10 days following chemotherapy and lasts one week to six weeks.
For more insights into disease, causes, and treatment, reach out to Oral Mucositis Treatment Landscape.
Oral Mucositis Epidemiology Segmentation
The Oral Mucositis Market report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
- Oral Mucositis Prevalence
- Age-Specific Oral Mucositis Prevalence
- Gender-Specific Oral Mucositis Prevalence
- Diagnosed and Treatable Cases of Oral Mucositis
Visit for more @ Oral Mucositis Epidemiological Insights.
Oral Mucositis Market
Oral mucositis has traditionally been treated with palliative care, while focused treatment strategies are currently being developed. Although it is impossible to prevent mucositis from developing, some steps can be taken before starting radiation.
Patients’ compliance and education, hydration, nutritional support, saline rinses, topical and systemic pain medication, and infection surveillance and treatment were all part of the traditional management of oral mucositis.
Palliative therapies such as palifermin and benzydamine have also been utilized in rare circumstances. Oral mucositis caused by cancer treatments is widely recognized as chemotherapy and radiation therapy’s most debilitating side effect.
Oral Mucositis Pipeline Therapies and Key Companies
- Avasopasem (GC4419): Galera Therapeutics
- SGX942: Soligenix
- Validive (Clonidine Lauriad): Monopar Therapeutics
- CareMin650: NeoMedLight
- Cooral/CoolPrevent: BrainCool
- MuReva Phototherapy System: MuReva (Lumitex)
- BupiZenge: Oncozenge
For more information, visit Oral Mucositis Market Analysis, Patient Pool, and Emerging Therapies.
Oral Mucositis Market Drivers
- Rising prevalent population
- Technological advancements
- Emerging therapies
- Extensive R&D
Scope of the Report
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Oral Mucositis, covering causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
- Comprehensive insight into Oral Mucositis epidemiology and treatment in the 7MM
- Current and emerging therapies for Oral Mucositis
- Oral Mucositis market drivers and barriers
Key Questions Answered in the Report
- What was the Oral Mucositis market share (%) distribution in 2017, and how would it look in 2030?
- What would be the Oral Mucositis total market size and market size by therapies across the 7MM during the forecast period (2017-2030)?
- What are the key findings of the market across 7MM, and which country will have the largest Oral Mucositis market size during the forecast period (2017-2030)?
- At what CAGR, the Oral Mucositis market is expected to grow by 7MM during the forecast period (2017-2030)?
Get in touch with our Business executive @ Oral Mucositis Market Landscape Analysis.
Table of Contents
1. | Key Insights |
2. | Report Introduction |
3. | Competitive Intelligence Analysis for Oral Mucositis |
4. | Oral Mucositis Market Overview at a Glance |
5. | Executive Summary of Oral Mucositis |
6. | Oral Mucositis Epidemiology and Market Methodology |
7. | Oral Mucositis Epidemiology and Patient Population |
8. | Oral Mucositis Patient Journey |
9. | Treatment Algorithm, Current Treatment, and Medical Practices |
10. | Key Endpoints in Oral Mucositis Clinical Trials |
11. | Oral Mucositis Marketed Therapies |
12. | Oral Mucositis Emerging Therapies |
13. | Oral Mucositis: 7 Major Market Analysis |
14. | Attribute analysis |
15. | Access and Reimbursement Overview of Oral Mucositis |
16. | KOL Reviews |
17. | Case Reports |
18. | Oral Mucositis Market Drivers |
19. | Oral Mucositis Market Barriers |
20. | SWOT Analysis |
21. | Disclaimer |
22. | DelveInsight Capabilities |
23. | About DelveInsight |
Learn more about the report offerings @ Oral Mucositis Market Outlook
Related Reports:
DelveInsight’s ‘Oral Mucositis (OM) – Market Insights, Epidemiology, and Market Forecast —2030’ report.
DelveInsight’s ‘Oral Mucositis (OM) – Epidemiology Forecast to 2030’ report.
DelveInsight’s ‘Oral Mucositis Pipeline Insights, 2021’ report.
Latest Reports:
Intrahepatic Cholangiocarcinoma (ICCA) Market
DelveInsight’s ‘Intrahepatic Cholangiocarcinoma (ICCA) – Market Insights, Epidemiology, and Market Forecast–2030’ report.
COVID 19 Therapeutic Pipeline, Vaccines, and Diagnostics Competitive Landscape, 2020
DelveInsight’s ‘COVID 19 (Novel Coronavirus 19) Therapeutic Pipeline, Vaccines, and Diagnostics Competitive Landscape, 2020’ report.
DelveInsight’s “Cervical Dysplasia – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight’s “Agoraphobia – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight’s “Hydrocephalus – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight’s ‘Sarcopenia–Market Insights, Epidemiology, and Market Forecast-2030’ report.
Diabetic Kidney Disease Market
DelveInsight’s “Diabetic Kidney Disease (DKD) – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight’s ‘Acromegaly-Market Insights, Epidemiology, and Market Forecast–2030’ report.
Acute Respiratory Distress Syndrome (ARDS) Market
DelveInsight’s ‘Acute Respiratory Distress Syndrome (ARDS) – Market Insights, Epidemiology and Market Forecast – 2030’ report.
Acute Kidney Injury (AKI) Market
DelveInsight’s ‘Acute Kidney Injury (AKI) – Market Insights, Epidemiology and Market Forecast– 2030’ report.
DelveInsight’s “Renal Anemia – Market Insights, Epidemiology, and Market Forecast-2030” report.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Information:
Kritika Rehani info@delveinsight.com +1(919)321-6187
Tags:
PR-Wirein, Reportedtimes, IPS, Menafn, Extended Distribution, iCN Internal Distribution, Research Newswire, English
Contact Information:
Kritika Rehani
info@delveinsight.com
+1(919)321-6187